Annals of the Rheumatic Diseases

1. Ann Rheum Dis2 May 2023

   Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies

   Mechanistic studyMyositis

2. Ann Rheum Dis21 Apr 2023

   Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

   Cohort studyLupus & APS

3. Ann Rheum Dis6 Apr 2023

   A meta-analysis and a functional study support the influence of mtDNA variant m.16519C on the risk of rapid progression of knee osteoarthritis

   Meta-analysisOsteoarthritis

4. Ann Rheum Dis5 Apr 2023

   Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

   Cohort studyRA

5. Ann Rheum Dis31 Mar 2023

   Efficacy and safety of emapalumab in macrophage activation syndrome

   Cohort studyPediatric

6. Ann Rheum Dis27 Mar 2023

   Increased risk of osteoarthritis in patients with atopic disease

   Cohort studyOsteoarthritis

7. Ann Rheum Dis23 Mar 2023

   Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

   Randomized controlled trialVasculitis & PMR

8. Ann Rheum Dis20 Mar 2023

   Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy

   Research articleOsteoporosis

9. Ann Rheum Dis17 Mar 2023

   Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

   Secondary analysisRA

10. Ann Rheum Dis14 Mar 2023

    Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance

    Mechanistic studyRA

11. Ann Rheum Dis3 Mar 2023

    Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

    Cohort studyRA

12. Ann Rheum Dis1 Mar 2023

    2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

    Guideline or statementAcross diseases

13. Ann Rheum Dis22 Feb 2023

    Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries

    Cohort studySpondyloarthritis & PsA

14. Ann Rheum Dis21 Feb 2023

    Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis

    Secondary analysisRA

15. Ann Rheum Dis17 Feb 2023

    What is a response in randomised controlled trials in giant cell arteritis?

    Research articleVasculitis & PMR

16. Ann Rheum Dis17 Feb 2023

    Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

    Mechanistic studyMyositis

17. Ann Rheum Dis16 Feb 2023

    Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

    Meta-analysisVasculitis & PMR

18. Ann Rheum Dis14 Feb 2023

    Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Cohort studySpondyloarthritis & PsA

19. Ann Rheum Dis14 Feb 2023

    Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme

    Cohort studyRA

20. Ann Rheum Dis31 Jan 2023

    Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis

    Research article

21. Ann Rheum Dis26 Jan 2023

    Risk factors for serious infections in ANCA-associated vasculitis

    Secondary analysisVasculitis & PMR

22. Ann Rheum Dis26 Jan 2023

    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022

    Guideline or statementAcross diseases

23. Ann Rheum Dis23 Jan 2023

    Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus

    Meta-analysisLupus & APS

24. Ann Rheum Dis18 Jan 2023

    Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation

    Secondary analysisSystemic sclerosis

25. Ann Rheum Dis17 Jan 2023

    Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

    Randomized controlled trialSpondyloarthritis & PsA

26. Ann Rheum Dis10 Jan 2023

    Human-specific duplicate CHRFAM7A gene is associated with more severe osteoarthritis and amplifies pain behaviours

    Mechanistic studyOsteoarthritis

27. Ann Rheum Dis10 Jan 2023

    Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis

    Meta-analysisRA

28. Ann Rheum Dis10 Jan 2023

    Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force

    Guideline or statementPediatric

29. Ann Rheum Dis26 Dec 2022

    Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies

    Mechanistic studyMyositis

30. Ann Rheum Dis23 Dec 2022

    Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis

    Mechanistic studyPediatric

31. Ann Rheum Dis23 Dec 2022

    Senescent cell population with ZEB1 transcription factor as its main regulator promotes osteoarthritis in cartilage and meniscus

    Mechanistic studyOsteoarthritis

32. Ann Rheum Dis21 Dec 2022

    Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis

    Diagnostic or prognostic studySpondyloarthritis & PsA

33. Ann Rheum Dis21 Dec 2022

    Piezo1-mediated mechanotransduction promotes entheseal pathological new bone formation in ankylosing spondylitis

    Mechanistic studySpondyloarthritis & PsA

34. Ann Rheum Dis21 Dec 2022

    Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial

    Cohort studyRA

35. Ann Rheum Dis16 Dec 2022

    Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis

    Meta-analysisRA

36. Ann Rheum Dis13 Dec 2022

    Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study

    Cohort studySpondyloarthritis & PsA

37. Ann Rheum Dis12 Dec 2022

    The provisional OMERACT ultrasonography score for giant cell arteritis

    Diagnostic or prognostic studyVasculitis & PMR

38. Ann Rheum Dis12 Dec 2022

    Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin

    Cross-sectional studySpondyloarthritis & PsA

39. Ann Rheum Dis6 Dec 2022

    Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking

    Case-control studyRA

40. Ann Rheum Dis5 Dec 2022

    Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis

    Case-control studySystemic sclerosis

All 596 Briefs in ExploreShowing Briefs 521–560 of 596, newest first